UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody

See also
	Status	Clinical Trial	Phase
	Completed	`NCT00171990` - Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes	Phase 3
	Not yet recruiting	`NCT04979975` - Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes	Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT00171990 - Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes

Phase 3

Not yet recruiting

NCT04979975 - Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes

Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04714060
Study type	Interventional
Source	UBP Greater China (Shanghai) Co., Ltd
Contact	Linda Shih, DVM
Phone	+886 36684800
Email	linda.shih@unitedbiopharma.com
Status	Not yet recruiting
Phase	Phase 2
Start date	October 1, 2023
Completion date	January 31, 2025

UB-621, a New Type of Anti-herpes Simplex Virus (HSV) Monoclonal Antibody for the Use in the Treatment of Adult Recurrent HSV-2 Infections of the Genitals

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms